Printer Friendly

AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.

Tokyo, Japan, July 26, 2005 - (JCNN) - AnGes MG announced on July 25 that the Pharmaceuticals and Medical Devices Agency (PMDA) has completed a preliminary 30-day examination of a clinical trial plan submitted by AnGes MG for NF-kappa B decoy oligodeoxynucleotide.

Accordingly, AnGes MG will soon start a phase I clinical trial by signing trial contracts with medical institutions. Specifically, the proposed clinical trial will seek the feasibility of NF-kappa B decoy oligodeoxynucleotide in the field of atopic dermatitis.

In addition, AnGes MG has partnered with Alfresa Pharma and jointly conducted research on NF-kappa B decoy oligodeoxynucleotide, aiming to apply it to atopic dermatitis.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jul 27, 2005
Words:119
Previous Article:Kobelco Eco-Solutions Develops Fuel Gas Generator That Uses Sewage Sludge.
Next Article:Chisso, Kobe University to Create New Company for Thermoresponsive Magnetic Nanoparticle Therma-Max.


Related Articles
Atopic dermatitis.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
AnGes MG Finally Starts Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
Hosokawa Micron, AnGes MG Succeed in Creating Composite Nanoparticle Contating NF-Kappa B Decoy Oligodeoxynucleotide.
AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters